loader2
Partner With Us NRI

Company details

616.70
637.05
560.00
1,022.50
6M Return -25.22%
1Y Return 2.17%
Mkt Cap.(Cr) 189.41
Volume 127
Div Yield 0.24%
OI
-
OI Chg %
-
Volume 127

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 129.21 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 26,236.77 -40,596.65
LAST 3M 79,235.45 -51,582.04
LAST 6M 145,414.64 -203,666.72
LAST 12M 206,629.88 -176,261.45
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
Sep 20, 2021 Dividend 15

Information

  • About Company
  • Company Info
  • Listing Info
12.37
68.96%
471.6819
12.53%
11.07%
Description
  • The Company was incorporated originally as "Potluri Real Estate Private Limited" on 31May, 2006 for undertaking the activities of real estate business and the Company could not commence business activities andthe company`s name has been changed to "Potluri Packaging Industries Private Limited" on 6 November, 2013. The Company could not undertake any such activities, once again the company`s name has been changed to "SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector. The Company has become a wholly owned subsidiary company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016. Subsequently converted into a Public Company under the Companies Act, 2013 w.e.f. 22 June, 2016. The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates. The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad. The Demerger Scheme sanctioned by the National Company Law Tribunal (NCLT) vide its order dated 15-05- 2017 received by the Company on 17-05-2017 has been implemented with appointed date as 01st April, 2016 as provided in the Scheme. Accordingly, the Semi Regulated Facilities i.e., Unit I, IV and V along with (i) premises situated at Industrial Estate, Sanath Nagar, Hyderabad; (ii) Industrial Development area, Jeedimetla, Hyderabad; (iii) Flat No. 417, Nilgiri, Aditya Enclave, Ameerpet, Hyderabad and (iv) Vacant Land admeasuring Ac 19.00 situated at Pharma City, Parawada, Vishakapatnam. Along with these assets the company has conferred with the liabilities mentioned in the books of the demerged company as on the appointed date. The Company allotted 30,23,287 equity shares of Rs.10 each to the shareholders of SMS Pharmaceuticals Limited (transferor Company) on 27 June, 2017 in pursuance of demerger scheme. Pursuant to the scheme of arrangement, the equity shares of the Company were listed in the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f 17 August 2017. During the FY2018,the Board approved the acquisition of Mahi Drugs Private Limited (Mahi Drugs), a Bulk Drugs manufacturing Company located at Vishakhapatnam, Andhra Pradesh, as a wholly owned (100%) subsidiary of SMS Lifesciences India Limited by entering into a share purchase agreement. During the FY2019, the Company had achieved production of 2040 M.T of APIs and their Intermediaries in comparison with 1729 M.T for the FY 2017-18. During the year 2018-19, Mahi Drugs Private Limited became wholly owned subsidiary of the Company with effect from 17 September, 2018. During the year 2019-20, producation has declined from 1,364 M.T. of API`s and their intermediates in comparison with 2,040 M.T. for the previous year due to the new USFDA guidelines on Ranitidine HCL The Company has received the prestigious "India Pharma Bulk Drugs Company of the year award" on 5 March, 2020 at the 5th edition of India Pharma and Medical Device 2020 conference organized by FICCI in collaboration with Ministry of Chemical and fertilizers, Govt. of India.

Read More

Registered Address

Plot No 19-III Road No 71, Opp Bharatiya Vidya Bhavan PSc, Hyderabad, Telangana, 500096

Tel : 91-040-6628-8888
Email : info:smslife.in
Website : http://www.smslife.in

Registrar

Aarthi Consultants Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 540679
NSE Code : SMSLIFE
Book Closure Date (Month) :
BSE Group : B
ISIN : INE320X01016

ICICIdirect SMS Lifesciences India Ltd FAQ

You can buy SMS Lifesciences India Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy SMS Lifesciences India Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 20, 2022 04:01 PM the closing price of SMS Lifesciences India Ltd was ₹ 626.55.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 20, 2022 04:01 PM, the market cap of SMS Lifesciences India Ltd stood at ₹ 189.41.
The latest PE ratio of SMS Lifesciences India Ltd as of May 20, 2022 04:01 PM is 12.37
The latest PB ratio of SMS Lifesciences India Ltd as of May 20, 2022 04:01 PM is 0.75
The 52-week high of SMS Lifesciences India Ltd is ₹ 1,022.50 while the 52-week low is ₹ 560.00 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE